Vaccines with aluminum-containing adjuvants: optimizing vaccine efficacy and thermal stability.
暂无分享,去创建一个
Dexiang Chen | Dexiang Chen | LaToya Jones Braun | Tanya Clapp | Paul Siebert | LaToya Jones Braun | Tanya Clapp | P. Siebert
[1] S. Joshi,et al. Structural stability of hepatitis C virus envelope glycoprotein E1: effect of pH and dissociative detergents. , 2009, Journal of pharmaceutical sciences.
[2] P. Marrack,et al. Towards an understanding of the adjuvant action of aluminium , 2009, Nature Reviews Immunology.
[3] J. White,et al. Mechanism of freeze-thaw instability of aluminum hydroxycarbonate and magnesium hydroxide gels. , 1984, Journal of pharmaceutical sciences.
[4] J. White,et al. Treatment of aluminium hydroxide adjuvant to optimize the adsorption of basic proteins. , 1996, Vaccine.
[5] Dexiang Chen,et al. Characterization of the freeze sensitivity of a hepatitis B vaccine , 2009, Human vaccines.
[6] L. Peek,et al. A systematic approach to stabilizing EBA-175 RII-NG for use as a malaria vaccine. , 2006, Vaccine.
[7] A. Glenny,et al. Rate of Disappearance of Diphtheria Toxoid injected into Rabbits and Guinea-Pigs: Toxoid precipitated with Alum. , 1931 .
[8] Martinus Løvik,et al. The capacity of particles to increase allergic sensitization is predicted by particle number and surface area, not by particle mass. , 2004, Toxicological sciences : an official journal of the Society of Toxicology.
[9] S. Hem,et al. Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation , 2007, Expert review of vaccines.
[10] J. Carpenter,et al. Dry powders of stable protein formulations from aqueous solutions prepared using supercritical CO(2)-assisted aerosolization. , 2001, Journal of pharmaceutical sciences.
[11] Aaron M. Smalter,et al. Stability of the Clostridium botulinum type A neurotoxin complex: an empirical phase diagram based approach. , 2007, Molecular pharmaceutics.
[12] R. Sitrin,et al. Relationship between tightness of binding and immunogenicity in an aluminum-containing adjuvant-adsorbed hepatitis B vaccine. , 2009, Vaccine.
[13] F. Regnier,et al. Effect of microenvironment pH of aluminum hydroxide adjuvant on the chemical stability of adsorbed antigen. , 2004, Vaccine.
[14] Henk C. Hoogsteden,et al. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells , 2008, The Journal of experimental medicine.
[15] F. Regnier,et al. Contribution of electrostatic and hydrophobic interactions to the adsorption of proteins by aluminium-containing adjuvants. , 1995, Vaccine.
[16] S. Jacobsen,et al. The structural stability of protein antigens adsorbed by aluminium hydroxide in comparison to the antigens in solutions , 2007 .
[17] K. Rock,et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization , 2008, Nature Immunology.
[18] E. Agger,et al. T‐helper 1 and T‐helper 2 adjuvants induce distinct differences in the magnitude, quality and kinetics of the early inflammatory response at the site of injection , 2010, Immunology.
[19] Jagadeesh Bayry,et al. Novel cellular and molecular mechanisms of induction of immune responses by aluminum adjuvants. , 2009, Trends in pharmacological sciences.
[20] H. HogenEsch,et al. Activation of dendritic cells and induction of CD4(+) T cell differentiation by aluminum-containing adjuvants. , 2007, Vaccine.
[21] Theodore W Randolph,et al. Influence of particle size and antigen binding on effectiveness of aluminum salt adjuvants in a model lysozyme vaccine. , 2008, Journal of pharmaceutical sciences.
[22] C. Stoldt,et al. Formation of Aqueous Small Droplet Aerosols Assisted by Supercritical Carbon Dioxide , 1999 .
[23] Dexiang Chen,et al. Development of a freeze-stable formulation for vaccines containing aluminum salt adjuvants. , 2009, Vaccine.
[24] S. Jacobsen,et al. Structural changes of protein antigens due to adsorption onto and release from aluminium hydroxide using FTIR–ATR , 2007 .
[25] Richard A. Flavell,et al. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants , 2008, Nature.
[26] J. Ježek,et al. A heat-stable hepatitis B vaccine formulation , 2009, Human vaccines.
[27] F. Regnier,et al. The in vitro displacement of adsorbed model antigens from aluminium-containing adjuvants by interstitial proteins. , 1999, Vaccine.
[28] M. Lal,et al. Characterization of a thermostable hepatitis B vaccine formulation. , 2009, Vaccine.
[29] J. Carpenter,et al. Evaluation of chemical degradation of a trivalent recombinant protein vaccine against botulinum neurotoxin by LysC peptide mapping and MALDI-TOF mass spectrometry. , 2009, Journal of pharmaceutical sciences.
[30] S. Hem,et al. Relationship between the degree of antigen adsorption to aluminum hydroxide adjuvant in interstitial fluid and antibody production. , 2003, Vaccine.
[31] P. Marrack,et al. How do adjuvants work? Important considerations for new generation adjuvants. , 2007, Immunity.
[32] C Russell Middaugh,et al. Derivative absorbance spectroscopy and protein phase diagrams as tools for comprehensive protein characterization: a bGCSF case study. , 2003, Journal of pharmaceutical sciences.
[33] S. Ausar,et al. High-throughput screening of stabilizers for Respiratory Syncytial Virus: Identification of stabilizers and their effects on the conformational thermostability of viral particles , 2007, Human vaccines.
[34] E. De Gregorio,et al. Immunology of TLR-independent vaccine adjuvants. , 2009, Current opinion in immunology.
[35] J. Paul Robinson,et al. Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro. , 2005, Vaccine.
[36] C. Braun,et al. Stabilizing formulations for inhalable powders of live-attenuated measles virus vaccine. , 2008, Journal of aerosol medicine and pulmonary drug delivery.
[37] R. Geahlen,et al. Effect of phosphorylation of ovalbumin on adsorption by aluminum-containing adjuvants and elution upon exposure to interstitial fluid. , 2005, Vaccine.
[38] R. Taub,et al. Considerable Differences in Vaccine Immunogenicities and Efficacies Related to the Diluent Used for Aluminum Hydroxide Adjuvant , 2008, Clinical and Vaccine Immunology.
[39] H. Hammad,et al. Mechanism of action of clinically approved adjuvants. , 2009, Current opinion in immunology.
[40] Dexiang Chen,et al. Stabilization of alum-adjuvanted vaccine dry powder formulations: mechanism and application. , 2003, Journal of pharmaceutical sciences.
[41] J. White,et al. Degree of antigen adsorption in the vaccine or interstitial fluid and its effect on the antibody response in rabbits. , 2001, Vaccine.
[42] M. Chevalier,et al. Secondary structure analysis of HIV-1-gp41 in solution and adsorbed to aluminum hydroxide by Fourier transform infrared spectroscopy. , 2007, Biochimica et biophysica acta.
[43] Jens Flemming,et al. Protection of aluminum hydroxide during lyophilisation as an adjuvant for freeze-dried vaccines , 2008 .
[44] F. Re,et al. Cutting Edge: Necrosis Activates the NLRP3 Inflammasome1 , 2009, The Journal of Immunology.
[45] J. White,et al. Predicting the adsorption of proteins by aluminium-containing adjuvants. , 1991, Vaccine.
[46] C Russell Middaugh,et al. Effect of pH and ionic strength on the physical stability of adenovirus type 5. , 2006, Journal of pharmaceutical sciences.
[47] L. Peek,et al. Effects of stabilizers on the destabilization of proteins upon adsorption to aluminum salt adjuvants. , 2007, Journal of pharmaceutical sciences.
[48] Anna Sokolovska,et al. Relationship between the strength of antigen adsorption to an aluminum-containing adjuvant and the immune response. , 2007, Vaccine.
[49] J. Carpenter,et al. Preparation of Active Proteins, Vaccines and Pharmaceuticals as Fine Powders using Supercritical or Near-Critical Fluids , 2008, Pharmaceutical Research.
[50] F. Re,et al. Aluminum Hydroxide Adjuvants Activate Caspase-1 and Induce IL-1β and IL-18 Release1 , 2007, The Journal of Immunology.
[51] B. Kerwin,et al. Secondary structures of proteins adsorbed onto aluminum hydroxide: infrared spectroscopic analysis of proteins from low solution concentrations. , 2006, Analytical biochemistry.
[52] S. Hem,et al. Mechanism of adsorption of hepatitis B surface antigen by aluminum hydroxide adjuvant. , 2004, Vaccine.
[53] K. Foster,et al. Association Between Immunogenicity and Adsorption of a Recombinant Streptococcus pneumoniae Vaccine Antigen by an Aluminum Adjuvant , 2006, Human vaccines.
[54] L. Peek,et al. Effects of Adsorption to Aluminum Salt Adjuvants on the Structure and Stability of Model Protein Antigens* , 2005, Journal of Biological Chemistry.
[55] V. Falcón,et al. Evidence for the denaturation of recombinant hepatitis B surface antigen on aluminium hydroxide gel. , 1998, Journal of chromatography. B, Biomedical sciences and applications.
[56] J. Arciniega,et al. Immunogenicity in mice of anthrax recombinant protective antigen in the presence of aluminum adjuvants. , 2005, Vaccine.
[57] G. Núñez,et al. The Nlrp3 inflammasome is critical for aluminium hydroxide‐mediated IL‐1β secretion but dispensable for adjuvant activity , 2008, European journal of immunology.
[58] Mark Hernandez,et al. Near-critical fluid micronization of stabilized vaccines, antibiotics and anti-virals , 2007 .
[59] S. Hem,et al. Effect of the Degree of Phosphate Substitution in Aluminum Hydroxide Adjuvant on the Adsorption of Phosphorylated Proteins , 2003, Pharmaceutical development and technology.
[60] J. Carpenter,et al. Inhibition of aggregation of aluminum hydroxide adjuvant during freezing and drying. , 2008, Journal of pharmaceutical sciences.
[61] H. HogenEsch,et al. Potentiation of the immune response to non-adsorbed antigens by aluminum-containing adjuvants. , 2007, Vaccine.
[62] Maya S. Salnikova,et al. Preformulation studies of Clostridium difficile toxoids A and B. , 2008, Journal of pharmaceutical sciences.
[63] J. Carpenter,et al. Stability of a trivalent recombinant protein vaccine formulation against botulinum neurotoxin during storage in aqueous solution. , 2009, Journal of pharmaceutical sciences.
[64] L. Peek,et al. A rapid, three-step process for the preformulation of a recombinant ricin toxin A-chain vaccine. , 2007, Journal of pharmaceutical sciences.
[65] S. Giardina,et al. Evaluation of the compatibility of a second generation recombinant anthrax vaccine with aluminum-containing adjuvants. , 2003, Vaccine.
[66] S. Hem,et al. Effect of the strength of adsorption of hepatitis B surface antigen to aluminum hydroxide adjuvant on the immune response. , 2009, Vaccine.
[67] A. Dong,et al. Effects of immobilization onto aluminum hydroxide particles on the thermally induced conformational behavior of three model proteins. , 2009, International journal of biological macromolecules.
[68] Michelle M. Garrison,et al. Freezing temperatures in the vaccine cold chain: a systematic literature review. , 2007, Vaccine.